Novo Nordisk's raised forecast fails to change the debate over its obesity business

Novo Nordisk raised its financial forecast, but the company's obesity drug business remains a point of debate among investors amid competition from Eli Lilly. The Danish pharmaceutical company manufactures Ozempic and Wegovy, medications used for diabetes and weight management. Analysts cited intensifying competition as a factor in their assessment of the company's growth trajectory.

Next story